Carlo Lombardi
Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper.
Zuberbier T, Dörr T, Aberer W, Alvaro-Lozano M, Angier E, Arasi S, Arshad H, Ballmer-Weber B, Bartra J, Beck L, Bégin P, Bindslev-Jensen C, Bislimovska J, Bousquet J, Brockow K, Bush A, Cianferoni A, Cork M, Custovic A, Darsow U, de Jong N, Deleanu D, Del Giacco S, Deschildre A, Dunn Galvin A, Ebisawa M, Fernández-Rivas M, Ferrer M, Fiocchi A, Gerth van Wijk R, Gotua M, Grimshaw K, Grünhagen J, Heffler E, Hide M, Hoffmann-Sommergruber K, Incorvaia C, Janson C, John S, Jones C, Jutel M, Katoh N, Kendziora B, Kinaciyan T, Knol E, Kurbacheva O, Lau S, Loh R, Lombardi C, Mäkelä M, Marchisotto M, Makris M, Maurer M, Meyer R, Mijakoski D, Minov J, Mullol J, Nilsson C, Nowak-Wegrzyn A, Nwaru B, Odemyr M, Pajno G, Paudel S, Papadopoulos N, Renz H, Ricci G, Ring J, Rogala B, Sampson H, Senna G, Sitkauskiene B, Smith P, Stevanovic K, Stoleski S, Szajewska H, Tanaka A, Todo-Bom A, Topal F, Valovirta E, Van Ree R, Venter C, Wöhrl S, Wong G, Zhao Z, Worm M. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper. Allergy 2021; 77:1736-1750.
Nov 24, 2021Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper.
Nov 24, 2021Allergy 2021; 77:1736-1750
Zuberbier Torsten, Dörr Tamara, Aberer Werner, Alvaro-Lozano Montserrat, Angier Elizabeth, Arasi Stefania, Arshad Hasan, Ballmer-Weber Barbara, Bartra Joan, Beck Lisa, Bégin Philippe, Bindslev-Jensen Carsten, Bislimovska Jovanka, Bousquet Jean, Brockow Knut, Bush Andrew, Cianferoni Antonella, Cork Michael J, Custovic Adnan, Darsow Ulf, de Jong Nicolette, Deleanu Diana, Del Giacco Stefano, Deschildre Antoine, Dunn Galvin Audrey, Ebisawa Motohiro, Fernández-Rivas Montserrat, Ferrer Marta, Fiocchi Alessandro, Gerth van Wijk Roy, Gotua Maia, Grimshaw Kate E C, Grünhagen Josefine, Heffler Enrico, Hide Michihiro, Hoffmann-Sommergruber Karin, Incorvaia Cristoforo, Janson Christer, John Swen Malte, Jones Carla, Jutel Marek, Katoh Norito, Kendziora Benjamin, Kinaciyan Tamar, Knol Edward, Kurbacheva Oksana, Lau Susanne, Loh Richard, Lombardi Carlo, Mäkelä Mika, Marchisotto Mary Jane, Makris Michael, Maurer Marcus, Meyer Rosan, Mijakoski Dragan, Minov Jordan, Mullol Joaquim, Nilsson Caroline, Nowak-Wegrzyn Anna, Nwaru Bright I, Odemyr Mikela, Pajno Giovanni Battista, Paudel Sushil, Papadopoulos Nikolaos G, Renz Harald, Ricci Giampaolo, Ring Johannes, Rogala Barbara, Sampson Hugh A, Senna Gianenrico, Sitkauskiene Brigita, Smith Peter Kenneth, Stevanovic Katarina, Stoleski Sasho, Szajewska Hania, Tanaka Akio, Todo-Bom Ana, Topal Fatih Alexander, Valovirta Erkka, Van Ree Ronald, Venter Carina, Wöhrl Stefan, Wong George K C, Zhao Zuotao, Worm Margitta
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study
European EGPA Study Group, Moroni L, Fagni F, Bello F, Fiori D, Ribi C, Cohen Tervaert J, Bargagli E, Samson M, Hellmich B, Mohammad A, Vacca A, Roccatello D, Ramirez G, Nasser M, Emmi G, Vaglio A, Prisco D, Jayne D, Salvarani C, Iannone F, Seeliger B, Egan A, Padoan R, Firinu D, Toniati P, Marvisi C, Fraticelli P, Cinetto F, Berti A, Lombardi C, Baldini C, Novikov P, Lopalco G, Neumann T, Schiavon F, Del Giacco S, Franceschini F, Cottin V, Dagna L, Urban M, Alberici F, Folci M, Crimi C, Silvagni E, Monti S, Kernder A, Schroeder J, Espígol-Frigolé G, Moosig F, Parronchi P, Lunardi C, Quartuccio L, Sinico R, Negrini S, Bettiol A. Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study. Arthritis Rheumatol 2021
Aug 4, 2021Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study
Aug 4, 2021Arthritis Rheumatol 2021
European EGPA Study Group, Moroni Luca, Fagni Filippo, Bello Federica, Fiori Davide, Ribi Camillo, Cohen Tervaert Jan Willem, Bargagli Elena, Samson Maxime, Hellmich Bernhard, Mohammad Aladdin J, Vacca Angelo, Roccatello Dario, Ramirez Giuseppe Alvise, Nasser Mouhamad, Emmi Giacomo, Vaglio Augusto, Prisco Domenico, Jayne David, Salvarani Carlo, Iannone Florenzo, Seeliger Benjamin, Egan Allyson, Padoan Roberto, Firinu Davide, Toniati Paola, Marvisi Chiara, Fraticelli Paolo, Cinetto Francesco, Berti Alvise, Lombardi Carlo, Baldini Chiara, Novikov Pavel, Lopalco Giuseppe, Neumann Thomas, Schiavon Franco, Del Giacco Stefano, Franceschini Franco, Cottin Vincent, Dagna Lorenzo, Urban Maria Letizia, Alberici Federico, Folci Marco, Crimi Claudia, Silvagni Ettore, Monti Sara, Kernder Anna Luise, Schroeder Jan, Espígol-Frigolé Georgina, Moosig Frank, Parronchi Paola, Lunardi Claudio, Quartuccio Luca, Sinico Renato Alberto, Negrini Simone, Bettiol Alessandra